The DOI matches its Crossref record; 612 of the 626 references it cites were found in a registry or an index.
A comprehensive review of immune checkpoint inhibitors for cancer treatment
Abstract
Immunology-based therapies are emerging as an effective cancer treatment, using the body's immune system to target tumors. Immune checkpoints, which regulate immune responses to prevent tissue damage and autoimmunity, are often exploited by cancer cells to avoid destruction. The discovery of checkpoint proteins like PD-1/PD-L1 and CTLA-4 was pivotal in developing cancer immunotherapy. Immune checkpoint inhibitors (ICIs) have shown great success, with FDA-approved drugs like PD-1 inhibitors (Nivolumab, Pembrolizumab, Cemiplimab), PD-L1 inhibitors (Atezolizumab, Durvalumab, Avelumab), and CTLA-4 inhibitors (Ipilimumab, Tremelimumab), alongside LAG-3 inhibitor Relatlimab. Research continues on new checkpoints like TIM-3, VISTA, B7-H3, BTLA, and TIGIT. Biomarkers like PDL-1 expression, tumor mutation burden, interferon-γ presence, microbiome composition, and extracellular matrix characteristics play a crucial role in predicting responses to immunotherapy with checkpoint inhibitors. Despite their effectiveness, not all patients experience the same level of benefit, and organ-specific immune-related adverse events (irAEs) such as rash or itching, colitis, diarrhea, hyperthyroidism, and hypothyroidism may occur. Given the rapid advancements in this field and the variability in patient outcomes, there is an urgent need for a comprehensive review that consolidates the latest findings on immune checkpoint inhibitors, covering their clinical status, biomarkers, resistance mechanisms, strategies to overcome resistance, and associated adverse effects. This review aims to fill this gap by providing an analysis of the current clinical status of ICIs, emerging biomarkers, mechanisms of resistance, strategies to enhance therapeutic efficacy, and assessment of adverse effects. This review is crucial to furthering our understanding of ICIs and optimizing their application in cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–400 of 612
Antigen presentation to naive CD4 T cells in the lymph node
Itano, A. A., & Jenkins, M. K. (2003) · Nature Immunology · doi:10.1038/ni957 · Cited by 467
Lee, K. A., Thomas, A. M., Bolte, L. A., Björk, J. R., de Ruijter, L. K., Armanini, F., Asnicar, F., Blanco-Miguez, A., Board, R., Calbet-Llopart, N., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01695-5 · Cited by 464
The Intriguing History of Cancer Immunotherapy
Dobosz, P., & Dzieciątkowski, T. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02965 · Cited by 458
Survival with Cemiplimab in Recurrent Cervical Cancer
Tewari, K. S., Monk, B. J., Vergote, I., Miller, A., de Melo, A. C., Kim, H.-S., Kim, Y. M., Lisyanskaya, A., Samouëlian, V., Lorusso, D., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2112187 · Cited by 458
The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors
Lin, D. Y.-W., Tanaka, Y., Iwasaki, M., Gittis, A. G., Su, H.-P., Mikami, B., Okazaki, T., Honjo, T., Minato, N., & Garboczi, D. N. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712278105 · Cited by 457
Wu, M., Huang, Q., Xie, Y., Wu, X., Ma, H., Zhang, Y., & Xia, Y. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01242-2 · Cited by 456
Wang, F., Wei, X. L., Wang, F. H., Xu, N., Shen, L., Dai, G. H., Yuan, X. L., Chen, Y., Yang, S. J., Shi, J. H., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz197 · Cited by 455
HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade
Woods, D. M., Sodré, A. L., Villagra, A., Sarnaik, A., Sotomayor, E. M., & Weber, J. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0077-t · Cited by 454
Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma
Gide, T. N., Wilmott, J. S., Scolyer, R. A., & Long, G. V. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2267 · Cited by 454
Vinayak, S., Tolaney, S. M., Schwartzberg, L., Mita, M., McCann, G., Tan, A. R., Wahner-Hendrickson, A. E., Forero, A., Anders, C., Wulf, G. M., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1029 · Cited by 454
Siglecs as Immune Cell Checkpoints in Disease
Duan, S., & Paulson, J. C. (2020) · Annual Review of Immunology · doi:10.1146/annurev-immunol-102419-035900 · Cited by 452
CD28/B7 Costimulation: A Review
Greenfield, E. A., Nguyen, K. A., & Kuchroo, V. K. (1998) · Critical Reviews™ in Immunology · doi:10.1615/critrevimmunol.v18.i5.10 · Cited by 441
Disis, M. L., Taylor, M. H., Kelly, K., Beck, J. T., Gordon, M., Moore, K. M., Patel, M. R., Chaves, J., Park, H., Mita, A. C., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.6258 · Cited by 437
TIGIT and CD 96: new checkpoint receptor targets for cancer immunotherapy
Dougall, W. C., Kurtulus, S., Smyth, M. J., & Anderson, A. C. (2017) · Immunological Reviews · doi:10.1111/imr.12518 · Cited by 435
The emerging role of epigenetic therapeutics in immuno-oncology
Topper, M. J., Vaz, M., Marrone, K. A., Brahmer, J. R., & Baylin, S. B. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0266-5 · Cited by 433
Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors
Lei, Q., Wang, D., Sun, K., Wang, L., & Zhang, Y. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00672 · Cited by 421
mTOR , metabolism, and the regulation of T‐cell differentiation and function
Waickman, A. T., & Powell, J. D. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01152.x · Cited by 420
Adenosine receptors and brain diseases: neuroprotection and neurodegeneration
Gomes, C. V., Kaster, M. P., Tomé, A. R., Agostinho, P. M., & Cunha, R. A. (2011) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2010.12.001 · Cited by 419
Zhu, Y., Yang, J., Xu, D., Gao, X.-M., Zhang, Z., Hsu, J. L., Li, C.-W., Lim, S.-O., Sheng, Y.-Y., Zhang, Y., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318419 · Cited by 419
Arce Vargas, F., Furness, A. J. S., Solomon, I., Joshi, K., Mekkaoui, L., Lesko, M. H., Miranda Rota, E., Dahan, R., Georgiou, A., Sledzinska, A., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.03.013 · Cited by 418
TIGIT: A Key Inhibitor of the Cancer Immunity Cycle
Manieri, N. A., Chiang, E. Y., & Grogan, J. L. (2017) · Trends in Immunology · doi:10.1016/j.it.2016.10.002 · Cited by 415
RasGRP is essential for mouse thymocyte differentiation and TCR signaling
Dower, N. A., Stang, S. L., Bottorff, D. A., Ebinu, J. O., Dickie, P., Ostergaard, H. L., & Stone, J. C. (2000) · Nature Immunology · doi:10.1038/79766 · Cited by 411
Structural and Functional Analysis of the Costimulatory Receptor Programmed Death-1
Zhang, X., Schwartz, J.-C. D., Guo, X., Bhatia, S., Cao, E., Chen, L., Zhang, Z.-Y., Edidin, M. A., Nathenson, S. G., & Almo, S. C. (2004) · Immunity · doi:10.1016/s1074-7613(04)00051-2 · Cited by 410
VISTA is an acidic pH-selective ligand for PSGL-1
Johnston, R. J., Su, L. J., Pinckney, J., Critton, D., Boyer, E., Krishnakumar, A., Corbett, M., Rankin, A. L., Dibella, R., Campbell, L., et al. (2019) · Nature · doi:10.1038/s41586-019-1674-5 · Cited by 402
CD39/CD73/A2AR pathway and cancer immunotherapy
Xia, C., Yin, S., To, K. K. W., & Fu, L. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01733-x · Cited by 399
Soares, K. C., Rucki, A. A., Wu, A. A., Olino, K., Xiao, Q., Chai, Y., Wamwea, A., Bigelow, E., Lutz, E., Liu, L., et al. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000062 · Cited by 398
Wang, J., Lu, S., Yu, X., Hu, Y., Sun, Y., Wang, Z., Zhao, J., Yu, Y., Hu, C., Yang, K., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.0366 · Cited by 396
Mai, H.-Q., Chen, Q.-Y., Chen, D., Hu, C., Yang, K., Wen, J., Li, J., Shi, Y.-R., Jin, F., Xu, R., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01444-0 · Cited by 396
Berner, F., Bomze, D., Diem, S., Ali, O. H., Fässler, M., Ring, S., Niederer, R., Ackermann, C. J., Baumgaertner, P., Pikor, N., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0402 · Cited by 395
Rangachari, M., Zhu, C., Sakuishi, K., Xiao, S., Karman, J., Chen, A., Angin, M., Wakeham, A., Greenfield, E. A., Sobel, R. A., et al. (2012) · Nature Medicine · doi:10.1038/nm.2871 · Cited by 394
Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer
Kwon, E. D., Hurwitz, A. A., Foster, B. A., Madias, C., Feldhaus, A. L., Greenberg, N. M., Burg, M. B., & Allison, J. P. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.15.8099 · Cited by 394
B7-H3: An Attractive Target for Antibody-based Immunotherapy
Kontos, F., Michelakos, T., Kurokawa, T., Sadagopan, A., Schwab, J. H., Ferrone, C. R., & Ferrone, S. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2584 · Cited by 389
Mitchell, T. C., Hamid, O., Smith, D. C., Bauer, T. M., Wasser, J. S., Olszanski, A. J., Luke, J. J., Balmanoukian, A. S., Schmidt, E. V., Zhao, Y., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.9602 · Cited by 388
The B7 family of immune-regulatory ligands.
Collins, M. A., Ling, V., & Carreno, B. M. (2005) · Genome biology · doi:10.1186/gb-2005-6-6-223 · Cited by 388
Huang, R.-Y., Francois, A., McGray, A. R., Miliotto, A., & Odunsi, K. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1249561 · Cited by 388
Hu, J., Yu, A., Othmane, B., Qiu, D., Li, H., Li, C., Liu, P., Ren, W., Chen, M., Gong, G., et al. (2021) · Theranostics · doi:10.7150/thno.53649 · Cited by 387
The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy
Long, L., Zhang, X., Chen, F., Pan, Q., Phiphatwatchara, P., Zeng, Y., & Chen, H. (2018) · Genes & Cancer · doi:10.18632/genesandcancer.180 · Cited by 386
Improved Survival with T Cell Clonotype Stability After Anti–CTLA-4 Treatment in Cancer Patients
Cha, E., Klinger, M., Hou, Y., Cummings, C., Ribas, A., Faham, M., & Fong, L. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008211 · Cited by 383
Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic Leukemia
Chao, M. P., Alizadeh, A. A., Tang, C., Jan, M., Weissman-Tsukamoto, R., Zhao, F., Park, C. Y., Weissman, I. L., & Majeti, R. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2238 · Cited by 382
Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls
Darnell, E. P., Mooradian, M. J., Baruch, E. N., Yilmaz, M., & Reynolds, K. L. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-0897-9 · Cited by 380
TIM-3 restrains anti-tumour immunity by regulating inflammasome activation
Dixon, K. O., Tabaka, M., Schramm, M. A., Xiao, S., Tang, R., Dionne, D., Anderson, A. C., Rozenblatt-Rosen, O., Regev, A., & Kuchroo, V. K. (2021) · Nature · doi:10.1038/s41586-021-03626-9 · Cited by 372
Cancer immunotherapy: a brief review of the history, possibilities, and challenges ahead
Oiseth, S. J., & Aziz, M. S. (2017) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2017.41 · Cited by 369
Regulation of JNK and p38 MAPK in the immune system: Signal integration, propagation and termination
Huang, G., Shi, L. Z., & Chi, H. (2009) · Cytokine · doi:10.1016/j.cyto.2009.08.002 · Cited by 368
Govindan, R., Szczesna, A., Ahn, M.-J., Schneider, C.-P., Gonzalez Mella, P. F., Barlesi, F., Han, B., Ganea, D. E., Von Pawel, J., Vladimirov, V., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.7629 · Cited by 365
Oaknin, A., Tinker, A. V., Gilbert, L., Samouëlian, V., Mathews, C., Brown, J., Barretina-Ginesta, M.-P., Moreno, V., Gravina, A., Abdeddaim, C., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.4515 · Cited by 364
Curigliano, G., Gelderblom, H., Mach, N., Doi, T., Tai, D., Forde, P. M., Sarantopoulos, J., Bedard, P. L., Lin, C.-C., Hodi, F. S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4746 · Cited by 362
Schoenfeld, J. D., Hanna, G. J., Jo, V. Y., Rawal, B., Chen, Y.-H., Catalano, P. S., Lako, A., Ciantra, Z., Weirather, J. L., Criscitiello, S., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.2955 · Cited by 361
Hodi, F. S., Lee, S., McDermott, D. F., Rao, U. N., Butterfield, L. H., Tarhini, A. A., Leming, P., Puzanov, I., Shin, D., & Kirkwood, J. M. (2014) · JAMA · doi:10.1001/jama.2014.13943 · Cited by 359
Fuchs, A., Cella, M., Giurisato, E., Shaw, A. S., & Colonna, M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.7.3994 · Cited by 358
Vstm3 is a member of the CD28 family and an important modulator of T‐cell function
Levin, S. D., Taft, D. W., Brandt, C. S., Bucher, C., Howard, E. D., Chadwick, E. M., Johnston, J., Hammond, A., Bontadelli, K., Ardourel, D., et al. (2011) · European Journal of Immunology · doi:10.1002/eji.201041136 · Cited by 356
Calabrò, L., Morra, A., Fonsatti, E., Cutaia, O., Amato, G., Giannarelli, D., Di Giacomo, A. M., Danielli, R., Altomonte, M., Mutti, L., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70381-4 · Cited by 356
He, W., Zhang, H., Han, F., Chen, X., Lin, R., Wang, W., Qiu, H., Zhuang, Z., Liao, Q., Zhang, W., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0381 · Cited by 355
Cancer immunotherapy targeting the CD47/SIRPα axis
Weiskopf, K. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.02.013 · Cited by 353
Zhou, X., Yao, Z., Yang, H., Liang, N., Zhang, X., & Zhang, F. (2020) · BMC Medicine · doi:10.1186/s12916-020-01549-2 · Cited by 353
Workman, C. J., Cauley, L. S., Kim, I.-J., Blackman, M. A., Woodland, D. L., & Vignali, D. A. A. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.9.5450 · Cited by 351
Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities
Kim, T. K., Vandsemb, E. N., Herbst, R. S., & Chen, L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00493-5 · Cited by 351
Liu, C., Liu, X., Xiang, X., Pang, X., Chen, S., Zhang, Y., Ren, E., Zhang, L., Liu, X., Lv, P., et al. (2022) · Nature Nanotechnology · doi:10.1038/s41565-022-01098-0 · Cited by 350
At the Bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy
Callahan, M. K., & Wolchok, J. D. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1212631 · Cited by 348
Zamarin, D., Burger, R. A., Sill, M. W., Powell, D. J., Lankes, H. A., Feldman, M. D., Zivanovic, O., Gunderson, C., Ko, E., Mathews, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02059 · Cited by 345
Shiratori, T., Miyatake, S., Ohno, H., Nakaseko, C., Isono, K., Bonifacino, J. S., & Saito, T. (1997) · Immunity · doi:10.1016/s1074-7613(00)80346-5 · Cited by 345
Neoadjuvant relatlimab and nivolumab in resectable melanoma
Amaria, R. N., Postow, M., Burton, E. M., Tetzlaff, M. T., Ross, M. I., Torres-Cabala, C., Glitza, I. C., Duan, F., Milton, D. R., Busam, K., et al. (2022) · Nature · doi:10.1038/s41586-022-05368-8 · Cited by 345
Liu, S., Zhang, H., Li, M., Hu, D., Li, C., Ge, B., Jin, B., & Fan, Z. (2013) · Cell Death & Differentiation · doi:10.1038/cdd.2012.141 · Cited by 342
Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells
Kamiya, T., Seow, S. V., Wong, D., Robinson, M., & Campana, D. (2019) · Journal of Clinical Investigation · doi:10.1172/jci123955 · Cited by 342
Immune-related adverse events and the balancing act of immunotherapy
Conroy, M., & Naidoo, J. (2022) · Nature Communications · doi:10.1038/s41467-022-27960-2 · Cited by 342
LAG-3 as the third checkpoint inhibitor
Aggarwal, V., Workman, C. J., & Vignali, D. A. A. (2023) · Nature Immunology · doi:10.1038/s41590-023-01569-z · Cited by 341
Zheng, H., Zhao, W., Yan, C., Watson, C. C., Massengill, M., Xie, M., Massengill, C., Noyes, D. R., Martinez, G. V., Afzal, R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2584 · Cited by 340
Immune checkpoint inhibitors in challenging populations
Johnson, D. B., Sullivan, R. J., & Menzies, A. M. (2017) · Cancer · doi:10.1002/cncr.30642 · Cited by 339
The Role of Calcium–Calcineurin–NFAT Signaling Pathway in Health and Autoimmune Diseases
Park, Y.-J., Yoo, S.-A., Kim, M., & Kim, W.-U. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00195 · Cited by 335
Wojtukiewicz, M. Z., Rek, M. M., Karpowicz, K., Górska, M., Polityńska, B., Wojtukiewicz, A. M., Moniuszko, M., Radziwon, P., Tucker, S. C., & Honn, K. V. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09976-0 · Cited by 335
Understanding the tumor microenvironment for effective immunotherapy
Sadeghi Rad, H., Monkman, J., Warkiani, M. E., Ladwa, R., O'Byrne, K., Rezaei, N., & Kulasinghe, A. (2021) · Medicinal Research Reviews · doi:10.1002/med.21765 · Cited by 334
Verma, V., Shrimali, R. K., Ahmad, S., Dai, W., Wang, H., Lu, S., Nandre, R., Gaur, P., Lopez, J., Sade-Feldman, M., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0441-y · Cited by 333
Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma
Gross, N. D., Miller, D. M., Khushalani, N. I., Divi, V., Ruiz, E. S., Lipson, E. J., Meier, F., Su, Y. B., Swiecicki, P. L., Atlas, J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2209813 · Cited by 333
The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy
Zingg, D., Arenas-Ramirez, N., Sahin, D., Rosalia, R. A., Antunes, A. T., Haeusel, J., Sommer, L., & Boyman, O. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.07.007 · Cited by 330
Lee, Y.-H., Martin-Orozco, N., Zheng, P., Li, J., Zhang, P., Tan, H., Park, H. J., Jeong, M., Chang, S. H., Kim, B.-S., et al. (2017) · Cell Research · doi:10.1038/cr.2017.90 · Cited by 328
Histone deacetylase 6 in cancer
Li, T., Zhang, C., Hassan, S., Liu, X., Song, F., Chen, K., Zhang, W., & Yang, J. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0654-9 · Cited by 326
Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer
Granier, C., De Guillebon, E., Blanc, C., Roussel, H., Badoual, C., Colin, E., Saldmann, A., Gey, A., Oudard, S., & Tartour, E. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000213 · Cited by 324
Shen, L., Kato, K., Kim, S.-B., Ajani, J. A., Zhao, K., He, Z., Yu, X., Shu, Y., Luo, Q., Wang, J., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01926 · Cited by 322
Gogishvili, M., Melkadze, T., Makharadze, T., Giorgadze, D., Dvorkin, M., Penkov, K., Laktionov, K., Nemsadze, G., Nechaeva, M., Rozhkova, I., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01977-y · Cited by 316
Wang, B., Zhao, Q., Zhang, Y., Liu, Z., Zheng, Z., Liu, S., Meng, L., Xin, Y., & Jiang, X. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01820-7 · Cited by 315
Powell, L. D., & Varki, A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.24.14243 · Cited by 312
T cell anergy and costimulation
Appleman, L. J., & Boussiotis, V. A. (2003) · Immunological Reviews · doi:10.1034/j.1600-065x.2003.00009.x · Cited by 305
Herbst, R. S., Majem, M., Barlesi, F., Carcereny, E., Chu, Q., Monnet, I., Sanchez-Hernandez, A., Dakhil, S., Camidge, D. R., Winzer, L., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00227 · Cited by 304
Sun, H., Huang, Q., Huang, M., Wen, H., Lin, R., Zheng, M., Qu, K., Li, K., Wei, H., Xiao, W., et al. (2019) · Hepatology · doi:10.1002/hep.30347 · Cited by 300
Characterization of Mouse and Human B7-H3 Genes
Sun, M., Richards, S., Prasad, D. V. R., Mai, X. M., Rudensky, A., & Dong, C. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.12.6294 · Cited by 295
B7-H3/CD276: An Emerging Cancer Immunotherapy
Zhou, W.-T., & Jin, W.-L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.701006 · Cited by 295
The role of CD28 and cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4) in regulatory T‐cell biology
Sansom, D. M., & Walker, L. S. K. (2006) · Immunological Reviews · doi:10.1111/j.0105-2896.2006.00419.x · Cited by 293
Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma
Sangro, B., Chan, S. L., Meyer, T., Reig, M., El-Khoueiry, A., & Galle, P. R. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.021 · Cited by 293
CTLA4 gene polymorphism and autoimmunity
Gough, S. C. L., Walker, L. S. K., & Sansom, D. M. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00249.x · Cited by 288
Tahara-Hanaoka, S. (2004) · International Immunology · doi:10.1093/intimm/dxh059 · Cited by 286
Phosphotyrosine-Dependent Coupling of Tim-3 to T-Cell Receptor Signaling Pathways
Lee, J., Su, E. W., Zhu, C., Hainline, S., Phuah, J., Moroco, J. A., Smithgall, T. E., Kuchroo, V. K., & Kane, L. P. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.05297-11 · Cited by 285
Coinhibitory receptor PD-1H preferentially suppresses CD4+ T cell–mediated immunity
Flies, D. B., Han, X., Higuchi, T., Zheng, L., Sun, J., Ye, J. J., & Chen, L. (2014) · Journal of Clinical Investigation · doi:10.1172/jci74589 · Cited by 282
Molecular Characterization of Human 4Ig-B7-H3, a Member of the B7 Family with Four Ig-Like Domains
Steinberger, P., Majdic, O., Derdak, S. V., Pfistershammer, K., Kirchberger, S., Klauser, C., Zlabinger, G., Pickl, W. F., Stöckl, J., & Knapp, W. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.4.2352 · Cited by 276
Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor
Guo, L., Zhang, H., & Chen, B. (2017) · Journal of Cancer · doi:10.7150/jca.17144 · Cited by 275
Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier
Vafaei, S., Zekiy, A. O., Khanamir, R. A., Zaman, B. A., Ghayourvahdat, A., Azimizonuzi, H., & Zamani, M. (2022) · Cancer Cell International · doi:10.1186/s12935-021-02407-8 · Cited by 270
de Mingo Pulido, Á., Hänggi, K., Celias, D. P., Gardner, A., Li, J., Batista-Bittencourt, B., Mohamed, E., Trillo-Tinoco, J., Osunmakinde, O., Peña, R., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.04.019 · Cited by 270
A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC
Boles, K. S., Vermi, W., Facchetti, F., Fuchs, A., Wilson, T. J., Diacovo, T. G., Cella, M., & Colonna, M. (2009) · European Journal of Immunology · doi:10.1002/eji.200839116 · Cited by 268
The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion
Lu, C., Paschall, A. V., Shi, H., Savage, N., Waller, J. L., Sabbatini, M. E., Oberlies, N. H., Pearce, C., & Liu, K. (2017) · Journal of the National Cancer Institute · doi:10.1093/jnci/djw283 · Cited by 266
Qin, S., Kudo, M., Meyer, T., Bai, Y., Guo, Y., Meng, Z., Satoh, T., Marino, D., Assenat, E., Li, S., et al. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.4003 · Cited by 265
PD‐L1 co‐stimulation contributes to ligand‐induced T cell receptor down‐modulation on CD8 + T cells
Karwacz, K., Bricogne, C., MacDonald, D., Arce, F., Bennett, C. L., Collins, M., & Escors, D. (2011) · EMBO Molecular Medicine · doi:10.1002/emmm.201100165 · Cited by 265
VSIG‐3 as a ligand of VISTA inhibits human T‐cell function
Wang, J., Wu, G., Manick, B., Hernandez, V., Renelt, M., Erickson, C., Guan, J., Singh, R., Rollins, S., Solorz, A., et al. (2019) · Immunology · doi:10.1111/imm.13001 · Cited by 263
Li, M., Xia, P., Du, Y., Liu, S., Huang, G., Chen, J., Zhang, H., Hou, N., Cheng, X., Zhou, L., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.572420 · Cited by 259
An Overview of Cancer Treatment Modalities
Abbas, Z., & Rehman, S. (2018) · Neoplasm · doi:10.5772/intechopen.76558 · Cited by 258
Nakamura, T., Sato, T., Endo, R., Sasaki, S., Takahashi, N., Sato, Y., Hyodo, M., Hayakawa, Y., & Harashima, H. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002852 · Cited by 257
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts
Wang, Y., Zhang, H., Liu, C., Wang, Z., Wu, W., Zhang, N., Zhang, L., Hu, J., Luo, P., Zhang, J., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01325-0 · Cited by 257
Le Dréan, E., Vély, F., Olcese, L., Cambiaggi, A., Guia, S., Krystal, G., Gervois, N., Moretta, A., Jotereau, F., & Vivier, E. (1998) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199801)28:01<264::aid-immu264>3.0.co;2-o · Cited by 254
Structure and Chromosomal Localization of the Human PD-1 Gene (PDCD1)
Shinohara, T., Taniwaki, M., Ishida, Y., Kawaichi, M., & Honjo, T. (1994) · Genomics · doi:10.1006/geno.1994.1562 · Cited by 253
Structural Analysis of CTLA-4 Function In Vivo
Masteller, E. L., Chuang, E., Mullen, A. C., Reiner, S. L., & Thompson, C. B. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.10.5319 · Cited by 252
MHC Class II Engagement by Its Ligand LAG-3 (CD223) Contributes to Melanoma Resistance to Apoptosis
Hemon, P., Jean-Louis, F., Ramgolam, K., Brignone, C., Viguier, M., Bachelez, H., Triebel, F., Charron, D., Aoudjit, F., Al-Daccak, R., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002050 · Cited by 252
Ralph, C., Elkord, E., Burt, D. J., O'Dwyer, J. F., Austin, E. B., Stern, P. L., Hawkins, R. E., & Thistlethwaite, F. C. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2870 · Cited by 250
Morel, K. L., Sheahan, A. V., Burkhart, D. L., Baca, S. C., Boufaied, N., Liu, Y., Qiu, X., Cañadas, I., Roehle, K., Heckler, M., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00185-w · Cited by 250
Tsimberidou, A.-M. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2861-1 · Cited by 249
Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells
Kim, D., Wang, J., Willingham, S. B., Martin, R., Wernig, G., & Weissman, I. L. (2012) · Leukemia · doi:10.1038/leu.2012.141 · Cited by 249
Flies, D. B., Wang, S., Xu, H., & Chen, L. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100660 · Cited by 249
CD3/TCR complex‐associated lymphocyte activation gene‐3 molecules inhibit CD3/TCR signaling
Hannier, S., Tournier, M., Bismuth, G., & Triebel, F. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.8.4058 · Cited by 248
Rodriguez-Abreu, D., Johnson, M. L., Hussein, M. A., Cobo, M., Patel, A. J., Secen, N. M., Lee, K. H., Massuti, B., Hiret, S., Yang, J. C.-H., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.9503 · Cited by 244
Engagement of CD27 with its ligand CD70 provides a second signal for T cell activation.
Hintzen, R. Q., Lens, S. M. A., Lammers, K., Kuiper, H., Beckmann, M. P., & van Lier, R. A. W. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.6.2612 · Cited by 243
Chen, T. W., Razak, A. R., Bedard, P. L., Siu, L. L., & Hansen, A. R. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv182 · Cited by 243
Molecular and Cellular Functions of CTLA-4
Van Coillie, S., Wiernicki, B., & Xu, J. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-15-3266-5_2 · Cited by 243
New frontiers in immune checkpoint B7-H3 (CD276) research and drug development
Getu, A. A., Tigabu, A., Zhou, M., Lu, J., Fodstad, Ø., & Tan, M. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01751-9 · Cited by 243
Kirkwood, J. M., Lorigan, P., Hersey, P., Hauschild, A., Robert, C., McDermott, D., Marshall, M. A., Gomez-Navarro, J., Liang, J. Q., & Bulanhagui, C. A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2033 · Cited by 241
Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy
Pan, C., Liu, H., Robins, E., Song, W., Liu, D., Li, Z., & Zheng, L. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00862-w · Cited by 241
Marron, T. U., Fiel, M. I., Hamon, P., Fiaschi, N., Kim, E., Ward, S. C., Zhao, Z., Kim, J., Kennedy, P., Gunasekaran, G., et al. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00385-x · Cited by 239
Ascierto, P. A., Melero, I., Bhatia, S., Bono, P., Sanborn, R. E., Lipson, E. J., Callahan, M. K., Gajewski, T., Gomez-Roca, C. A., Hodi, F. S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.9520 · Cited by 238
Current understanding of CTLA-4: from mechanism to autoimmune diseases
Hossen, M. M., Ma, Y., Yin, Z., Xia, Y., Du, J., Huang, J. Y., Huang, J. J., Zou, L., Ye, Z., & Huang, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1198365 · Cited by 238
VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy
Lines, J. L., Sempere, L. F., Broughton, T., Wang, L., & Noelle, R. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0072 · Cited by 236
TIM-3, a promising target for cancer immunotherapy
He, Y., Cao, J., Zhao, C., Li, X., Zhou, C., & Hirsch, F. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s170385 · Cited by 235
Oldenborg, P.-A. (2013) · ISRN Hematology · doi:10.1155/2013/614619 · Cited by 235
Immune Escape and Survival Mechanisms in Circulating Tumor Cells of Colorectal Cancer
Steinert, G., Schölch, S., Niemietz, T., Iwata, N., García, S. A., Behrens, B., Voigt, A., Kloor, M., Benner, A., Bork, U., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1885 · Cited by 233
Costimulation of T cells by OX40, 4-1BB, and CD27
Croft, M. (2003) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(03)00025-x · Cited by 231
Klein, O., Kee, D., Nagrial, A., Markman, B., Underhill, C., Michael, M., Jackett, L., Lum, C., Behren, A., Palmer, J., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.2814 · Cited by 231
Regulatory T-Cells: Diverse Phenotypes Integral to Immune Homeostasis and Suppression
Peterson, R. A. (2012) · Toxicologic Pathology · doi:10.1177/0192623311430693 · Cited by 230
Cao, E., Zang, X., Ramagopal, U. A., Mukhopadhaya, A., Fedorov, A., Fedorov, E., Zencheck, W. D., Lary, J. W., Cole, J. L., Deng, H., et al. (2007) · Immunity · doi:10.1016/j.immuni.2007.01.016 · Cited by 228
A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy
Leone, R. D., Lo, Y.-C., & Powell, J. D. (2015) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2015.03.008 · Cited by 225
Motzer, R. J., Escudier, B., McDermott, D. F., Arén Frontera, O., Melichar, B., Powles, T., Donskov, F., Plimack, E. R., Barthélémy, P., Hammers, H. J., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000891 · Cited by 224
Control of signaling-mediated clearance of apoptotic cells by the tumor suppressor p53
Yoon, K. W., Byun, S., Kwon, E., Hwang, S.-Y., Chu, K., Hiraki, M., Jo, S.-H., Weins, A., Hakroush, S., Cebulla, A., et al. (2015) · Science · doi:10.1126/science.1261669 · Cited by 224
Larkin, J., Lao, C. D., Urba, W. J., McDermott, D. F., Horak, C., Jiang, J., & Wolchok, J. D. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.1184 · Cited by 223
Slow Down and Survive: Enigmatic Immunoregulation by BTLA and HVEM
Murphy, T. L., & Murphy, K. M. (2010) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101202 · Cited by 223
Liu, J. F., Herold, C., Gray, K. P., Penson, R. T., Horowitz, N., Konstantinopoulos, P. A., Castro, C. M., Hill, S. J., Curtis, J., Luo, W., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.3343 · Cited by 222
The costimulatory role of TIM molecules
Rodriguez‐Manzanet, R., DeKruyff, R., Kuchroo, V. K., & Umetsu, D. T. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00772.x · Cited by 221
The role of iron homeostasis in remodeling immune function and regulating inflammatory disease
Mu, Q., Chen, L., Gao, X., Shen, S., Sheng, W., Min, J., & Wang, F. (2021) · Science Bulletin · doi:10.1016/j.scib.2021.02.010 · Cited by 221
Calabrò, L., Morra, A., Giannarelli, D., Amato, G., D'Incecco, A., Covre, A., Lewis, A., Rebelatto, M. C., Danielli, R., Altomonte, M., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30151-6 · Cited by 218
TIM-3: An update on immunotherapy
Zhao, L., Cheng, S., Fan, L., Zhang, B., & Xu, S. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107933 · Cited by 217
Chocarro, L., Blanco, E., Zuazo, M., Arasanz, H., Bocanegra, A., Fernández-Rubio, L., Morente, P., Fernández-Hinojal, G., Echaide, M., Garnica, M., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105282 · Cited by 216
Lee, T. K.-W., Cheung, V. C.-H., Lu, P., Lau, E. Y. T., Ma, S., Tang, K. H., Tong, M., Lo, J., & Ng, I. O. L. (2014) · Hepatology · doi:10.1002/hep.27070 · Cited by 213
Sanchez-Correa, B., Valhondo, I., Hassouneh, F., Lopez-Sejas, N., Pera, A., Bergua, J. M., Arcos, M. J., Bañas, H., Casas-Avilés, I., Durán, E., et al. (2019) · Cancers · doi:10.3390/cancers11060877 · Cited by 213
Identification of CD112R as a novel checkpoint for human T cells
Zhu, Y., Paniccia, A., Schulick, A. C., Chen, W., Koenig, M. R., Byers, J. T., Yao, S., Bevers, S., & Edil, B. H. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20150785 · Cited by 211
Maruhashi, T., Sugiura, D., Okazaki, I.-M., Shimizu, K., Maeda, T. K., Ikubo, J., Yoshikawa, H., Maenaka, K., Ishimaru, N., Kosako, H., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.03.013 · Cited by 211
El Osta, B., Hu, F., Sadek, R., Chintalapally, R., & Tang, S.-C. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.09.002 · Cited by 209
Li, X., Khorsandi, S., Wang, Y., Santelli, J., Huntoon, K., Nguyen, N., Yang, M., Lee, D., Lu, Y., Gao, R., et al. (2022) · Nature Nanotechnology · doi:10.1038/s41565-022-01134-z · Cited by 209
Arrieta, O. G., Barrón, F., Ramírez-Tirado, L. A., Zatarain-Barrón, Z. L., Cardona, A. F., Díaz-García, D. A., Ramos, M. Y., Mota-Vega, B., Carmona, A., Álvarez, M. P. P., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.0409 · Cited by 208
CD4 and CD8 binding to MHC molecules primarily acts to enhance Lck delivery
Artyomov, M. N., Lis, M., Devadas, S., Davis, M. M., & Chakraborty, A. K. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1010568107 · Cited by 207
Calabrò, L., Morra, A., Fonsatti, E., Cutaia, O., Fazio, C., Annesi, D., Lenoci, M., Amato, G., Danielli, R., Altomonte, M., et al. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00092-2 · Cited by 206
The Role of OX40-Mediated Co-stimulation in T-Cell Activation and Survival
Redmond, W. L., Ruby, C. E., & Weinberg, A. D. (2009) · Critical Reviews™ in Immunology · doi:10.1615/critrevimmunol.v29.i3.10 · Cited by 205
Kappler, J., Kubo, R., Haskins, K., Hannum, C., Marrack, P., Pigeon, M., McIntyre, B., Allison, J., & Trowbridge, I. (1983) · Cell · doi:10.1016/0092-8674(83)90232-5 · Cited by 205
Siglec-15: an immune system Siglec conserved throughout vertebrate evolution
Angata, T., Tabuchi, Y., Nakamura, K., & Nakamura, M. (2007) · Glycobiology · doi:10.1093/glycob/cwm049 · Cited by 204
Tobin, R. P., Jordan, K. R., Robinson, W. A., Davis, D., Borges, V. F., Gonzalez, R., Lewis, K. D., & McCarter, M. D. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.08.007 · Cited by 204
VISTA expressed in tumour cells regulates T cell function
Mulati, K., Hamanishi, J., Matsumura, N., Chamoto, K., Mise, N., Abiko, K., Baba, T., Yamaguchi, K., Horikawa, N., Murakami, R., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0313-5 · Cited by 204
Hofmeyer, K. A., Ray, A., & Zang, X. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805458105 · Cited by 201
Limagne, E., Richard, C., Thibaudin, M., Fumet, J.-D., Truntzer, C., Lagrange, A., Favier, L., Coudert, B., & Ghiringhelli, F. (2019) · OncoImmunology · doi:10.1080/2162402x.2018.1564505 · Cited by 201
Nivolumab: Targeting PD-1 to Bolster Antitumor Immunity
Brahmer, J. R., Hammers, H., & Lipson, E. J. (2015) · Future Oncology · doi:10.2217/fon.15.52 · Cited by 199
Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy
Ai, L., Chen, J., Yan, H., He, Q., Luo, P., Xu, Z., & Yang, X. (2020) · Drug Design, Development and Therapy · doi:10.2147/dddt.s267433 · Cited by 199
A highly conserved tyrosine of Tim‐3 is phosphorylated upon stimulation by its ligand galectin‐9
van de Weyer, P. S., Muehlfeit, M., Klose, C., Bonventre, J. V., Walz, G., & Kuehn, E. W. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.10.079 · Cited by 198
mTOR signaling in the differentiation and function of regulatory and effector T cells
Zeng, H., & Chi, H. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.04.005 · Cited by 198
Wang, L., Le Mercier, I., Putra, J., Chen, W., Liu, J., Schenk, A. D., Nowak, E. C., Suriawinata, A. A., Li, J., & Noelle, R. J. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1407447111 · Cited by 195
Qin, S., Chen, Z., Fang, W., Ren, Z., Xu, R., Ryoo, B.-Y., Meng, Z., Bai, Y., Chen, X., Liu, X., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00620 · Cited by 195
Chao, M. P., Tang, C., Pachynski, R. K., Chin, R., Majeti, R., & Weissman, I. L. (2011) · Blood · doi:10.1182/blood-2011-02-338020 · Cited by 194
Protein kinase C theta (PKCθ): A key player in T cell life and death
HAYASHI, K., & ALTMAN, A. (2007) · Pharmacological Research · doi:10.1016/j.phrs.2007.04.009 · Cited by 193
Maçon‐Lemaître, L., & Triebel, F. (2005) · Immunology · doi:10.1111/j.1365-2567.2005.02145.x · Cited by 192
Zhang, G., Hou, J., Shi, J., Yu, G., Lu, B., & Zhang, X. (2008) · Immunology · doi:10.1111/j.1365-2567.2007.02723.x · Cited by 192
Li, B., VanRoey, M., Wang, C., Chen, T.-H. T., Korman, A., & Jooss, K. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1825 · Cited by 191
Herbst, R. S., Gordon, M. S., Fine, G. D., Sosman, J. A., Soria, J.-C., Hamid, O., Powderly, J. D., Burris, H. A., Mokatrin, A., Kowanetz, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.3000 · Cited by 190
Sanmamed, M. F., Pastor, F., Rodriguez, A., Perez-Gracia, J. L., Rodriguez-Ruiz, M. E., Jure-Kunkel, M., & Melero, I. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.014 · Cited by 190
Takamiya, R., Ohtsubo, K., Takamatsu, S., Taniguchi, N., & Angata, T. (2013) · Glycobiology · doi:10.1093/glycob/cws139 · Cited by 189
Calcium–NFAT transcriptional signalling in T cell activation and T cell exhaustion
Hogan, P. G. (2017) · Cell Calcium · doi:10.1016/j.ceca.2017.01.014 · Cited by 186
LAG3’s Enigmatic Mechanism of Action
Graydon, C. G., Mohideen, S., & Fowke, K. R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.615317 · Cited by 182
Wang, C. J., Heuts, F., Ovcinnikovs, V., Wardzinski, L., Bowers, C., Schmidt, E. M., Kogimtzis, A., Kenefeck, R., Sansom, D. M., & Walker, L. S. K. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1414576112 · Cited by 179
Dummer, R., Long, G. V., Robert, C., Tawbi, H. A., Flaherty, K. T., Ascierto, P. A., Nathan, P. D., Rutkowski, P., Leonov, O., Dutriaux, C., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01601 · Cited by 178
Ca2+/calcineurin signalling in cells of the immune system
Feske, S., Okamura, H., Hogan, P. G., & Rao, A. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.09.174 · Cited by 177
Huo, J.-L., Wang, Y.-T., Fu, W.-J., Lu, N., & Liu, Z.-S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.956090 · Cited by 176
Long, G. V., Weber, J. S., Larkin, J., Atkinson, V., Grob, J.-J., Schadendorf, D., Dummer, R., Robert, C., Márquez-Rodas, I., McNeil, C., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.1588 · Cited by 176
Fine tuning the immune response through B7‐H3 and B7‐H4
Yi, K. H., & Chen, L. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00768.x · Cited by 175
Bozec, A., Zaiss, M. M., Kagwiria, R., Voll, R., Rauh, M., Chen, Z., Mueller-Schmucker, S., Kroczek, R. A., Heinzerling, L., Moser, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007764 · Cited by 175
Inozume, T., Yaguchi, T., Furuta, J., Harada, K., Kawakami, Y., & Shimada, S. (2016) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.404 · Cited by 174
Wang, L., Amoozgar, Z., Huang, J., Saleh, M. H., Xing, D., Orsulic, S., & Goldberg, M. S. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0073 · Cited by 173
Constitutive Clathrin-mediated Endocytosis of CTLA-4 Persists during T Cell Activation
Qureshi, O. S., Kaur, S., Hou, T. Z., Jeffery, L. E., Poulter, N. S., Briggs, Z., Kenefeck, R., Willox, A. K., Royle, S. J., Rappoport, J. Z., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.304329 · Cited by 172
Essential role of HDAC6 in the regulation of PD‐L1 in melanoma
Lienlaf, M., Perez-Villarroel, P., Knox, T., Pabon, M., Sahakian, E., Powers, J., Woan, K. V., Lee, C., Cheng, F., Deng, S., et al. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2015.12.012 · Cited by 170
PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8+ T-cell Function
Whelan, S., Ophir, E., Kotturi, M. F., Levy, O., Ganguly, S., Leung, L., Vaknin, I., Kumar, S., Dassa, L., Hansen, K., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0442 · Cited by 169
Tumors establish resistance to immunotherapy by regulating T reg recruitment via CCR4
Marshall, L. A., Marubayashi, S., Jorapur, A., Jacobson, S., Zibinsky, M., Robles, O., Hu, D. X., Jackson, J. J., Pookot, D., Sanchez, J., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000764 · Cited by 169
Tang, B., Chi, Z., Chen, Y., Liu, X., Wu, D., Chen, J., Song, X., Wang, W., Dong, L., Song, H., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3922 · Cited by 168
Transmembrane Signaling by G Protein-Coupled Receptors
Luttrell, L. M. (2006) · Humana Press eBooks · doi:10.1385/1-59745-048-0:1 · Cited by 167
Rincón, M., Flavell, R. A., & Davis, R. A. (2000) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(00)00219-7 · Cited by 167
Releasing the Brakes on Cancer Immunotherapy
Littman, D. R. (2015) · Cell · doi:10.1016/j.cell.2015.08.038 · Cited by 166
Ascierto, P. A., Lipson, E. J., Dummer, R., Larkin, J., Long, G. V., Sanborn, R. E., Chiarion-Sileni, V., Dréno, B., Dalle, S., Schadendorf, D., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02072 · Cited by 166
4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy
Vinay, D. S., & Kwon, B. S. (2014) · BMB Reports · doi:10.5483/bmbrep.2014.47.3.283 · Cited by 165
Kim, J. Y., Kronbichler, A., Eisenhut, M., Hong, S. H., van der Vliet, H. J., Kang, J., Shin, J. I., & Gamerith, G. (2019) · Cancers · doi:10.3390/cancers11111798 · Cited by 165
Hassan, R., Thomas, A., Nemunaitis, J. J., Patel, M. R., Bennouna, J., Chen, F. L., Delord, J., Dowlati, A., Kochuparambil, S. T., Taylor, M. H., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5428 · Cited by 163
Schöffski, P., Tan, D. S. W., Martín, M., Ochoa-de-Olza, M., Sarantopoulos, J., Carvajal, R. D., Kyi, C., Esaki, T., Prawira, A., Akerley, W., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003776 · Cited by 163
The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy
Moran, A. E., Kovacsovics-Bankowski, M., & Weinberg, A. D. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.01.004 · Cited by 162
Lu, J.-C., Zhang, P.-F., Huang, X.-Y., Guo, X.-J., Gao, C., Zeng, H.-Y., Zheng, Y.-M., Wang, S.-W., Cai, J.-B., Sun, Q.-M., et al. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01207-x · Cited by 162
Doi, T., Muro, K., Ishii, H., Kato, T., Tsushima, T., Takenoyama, M., Oizumi, S., Gemmoto, K., Suna, H., Enokitani, K., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1090 · Cited by 161
Cited by
The Role of Immune Checkpoint Inhibitors in Cancer Therapy: Mechanism and Therapeutic Advances
Chen, H., Yang, H., Guo, L., & Sun, Q. (2025) · MedComm · doi:10.1002/mco2.70412 · Cited by 66
Li, J., Peng, J., Wang, J., & Chen, Z. (2025) · Med Research · doi:10.1002/mdr2.70022 · Cited by 62
Han, X., Zhang, J., Li, W., Huang, X., Wang, X., Wang, B., Gao, L., & Chen, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1512509 · Cited by 55
Roussot, N., Kaderbhaï, C., & Ghiringhelli, F. (2025) · Cancers · doi:10.3390/cancers17050906 · Cited by 34
Dendritic cell immunotherapy advances for solid tumors: Vaccination and modulation
Clayton, G., Toffoli, E. C., de Gruijl, T. D., & van Kooyk, Y. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102412 · Cited by 30
Metadata
- Authors
- Arafat Hossain, M.
- Venue
- International Immunopharmacology
- Publisher
- Elsevier BV
- Published
- 2024-12
- Volume
- 143
- Issue
- Pt 2
- Pages
- 113365
- ISSN
- 1567-5769 (ISSN-L)
- OpenAlex
- W4403679157
- Cited by
- 178
- References
- 626
- FWCI
- 27.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.